The researchers vaccinated with a live, fully active pathogen.
Photo: © Paul Mehnert / University of Tübingen

24.02.2017

<< First < Previous Page 1 Page 2 Page 3 Page 4 Page 5 Next > Last >>
In a clinical trial on malaria vaccination, researchers at the German University of Tübingen have achieved a protection of up to 100 per cent by using fully viable malaria parasites.

In collaboration with the biotech company Sanaria Inc., University of Tübingen researchers have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 per cent effective when assessed at ten weeks after its last dose. For the trial, Professor Peter Kremsner and Dr Benjamin Mordmüller of the Institute of Tropical Medicine and the German Center for Infection Research (DZIF) in Tübingen used malaria parasites provided by Sanaria. The vaccine incorporated fully viable – not weakened or otherwise inactivated – malaria pathogens together with the medication to combat them. Their research results have been published in the latest edition of Nature.

Malaria parasites are transmitted by the bite of female Anopheles mosquitoes. The Plasmodium falciparum parasite is responsible for most malaria infections and almost all deaths caused by the disease world-wide. The majority of the vaccines tried previously involved the use of individual molecules found in the pathogen.

<< First < Previous Page 1 Page 2 Page 3 Page 4 Page 5 Next > Last >>